Back

Real-world eligibility and cost-effectiveness of finerenone in heart failure: insights from the Korean heart failure III (KorHF III) registry

10 May 2026 (10:45 - 11:52)
Organised by: Logo
Congress Presentation Part of: ePosters in acute heart failure - epidemiology, prognosis, outcome (1) Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Moojun Kim

National Health Insurance Service (NHIS) Ilsan Hospital, Goyang (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail
Real-world one-year effectiveness and safety of vericiguat in patients with heart failure in Spain: results from the multicenter prospective VERISEC study
Doctor A. Esteban Fernandez (Leganes, ES)
Abstract Slides
Presentation thumbnail
Impact of total ischemic time on acute heart failure in stemi patients undergoing primary PCI
Professor H. Hayrapetyan (Yerevan, AM)
Abstract Slides
Presentation thumbnail
Complementary prognostic value of urine output and renal function in heart failure-related cardiogenic shock
Mr T. Ris (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
When youth meets risk: a simple score predicting heart failure after early-onset acute coronary syndrome
Doctor L. Brochado (Almada, PT)
Abstract Slides
Presentation thumbnail
Sex differences in clinical profile, management, and outcomes in heart failure: results from the Spanish SEC-Excelente National Registry
Doctor A. Esteban Fernandez (Leganes, ES)
Abstract Slides

Access the full session

Session thumbnail
ePosters in acute heart failure - epidemiology, prognosis, outcome (1)

The Event

Event poster

Heart Failure 2026

10 May 2026 10:45 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources